Oncology-focused RWE company using the COTA Grading System to classify cancer patients into clinically relevant subgroups for real-world evidence generation.
Vendor description
Oncology RWE with proprietary patient classification
Oncology RWE,Patient classification,Real-world outcomes analysis
- Proprietary COTA Grading System
- Oncology specialism
- Clinically relevant cohorts
- Outcomes-based analysis
- Oncology/hematology only
- Small company
- US-focused
Approved customer reviews
Write a reviewNo reviews yet
Be the first customer to share verified experience with this vendor.
Pricing
$
Key facts
| HQ country | United States |
|---|---|
| Geography | North America |
| Service model | SaaS + Data |
| Study phases | Phase II, Phase III, Phase IV |
| Trial scale | Small,Medium |
| Therapeutic areas | Oncology, Hematology |
Related vendors
Editorial ranking
See how COTA compares - best Biometrics / data science vendors for clinical trials.